Overview

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2023-11-13

Target enrollment:

Participant gender:

Summary

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care [SoC] CRT) in patients with locally advanced, unresectable NSCLC (Stage III).

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Carboplatin
Cisplatin
Durvalumab
Etoposide
Etoposide phosphate
Paclitaxel
Pemetrexed